S 1407 · 119th CongressIn Committeecongress.gov ↗
What this bill does
AI plain-language summaryThis bill would stop federal health care programs from buying drugs that contain active ingredients made in China or in countries that don't meet U.S. safety standards, with the rule fully taking effect by January 1, 2030. It also requires all drugs to list the country where each active ingredient was made on their labels, and drugs without this information would be considered mislabeled. Additionally, the bill gives tax breaks to companies that build or expand drug and medical device factories in the United States between 2025 and 2030.
Your Vote
Discussion (0)
Explain what is at stake in this bill.
Sign in to join the discussion.
No comments yet. Be the first.